Isidro B Salusky

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1462276/publications.pdf

Version: 2024-02-01

77	3,646	186265 28	133252 59
papers	citations	h-index	g-index

81	81	81	2559
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effects of Primary Kidney Disease Etiology on Renal Osteodystrophy in Pediatric Dialysis Patients. JBMR Plus, 2022, 6, e10601.	2.7	1
2	A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial. Pediatric Nephrology, 2022, 37, 2547-2557.	1.7	1
3	Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling. ELife, 2022, 11, .	6.0	18
4	Phase 1, single-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of etelcalcetide in pediatric patients with secondary hyperparathyroidism receiving hemodialysis. Pediatric Nephrology, 2021, 36, 133-142.	1.7	1
5	Regional variation in bone turnover at the iliac crest versus the greater trochanter. Bone, 2021, 143, 115604.	2.9	1
6	Vitamin C overload may contribute to systemic oxalosis in children receiving dialysis. Pediatric Nephrology, 2021, 36, 435-441.	1.7	9
7	Mineral bone disease in autosomal dominant polycystic kidney disease. Kidney International, 2021, 99, 977-985.	5.2	16
8	Correspondence on â€œProspective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI)â€•by Ferreira et al.. Genetics in Medicine, 2021, 23, 2006-2007.	2.4	10
9	Bone marrow adiposity inversely correlates with bone turnover in pediatric renal osteodystrophy. Bone Reports, 2021, 15, 101104.	0.4	0
10	Measurement of serum phosphate levels using a mobile sensor. Analyst, The, 2020, 145, 1841-1848.	3.5	13
11	The Authors Reply. Kidney International Reports, 2020, 5, 1119-1120.	0.8	0
12	Nephropathic Cystinosis: A Distinct Form of CKDâ€“Mineral and Bone Disorder that Provides Novel Insights into the Regulation of FGF23. Journal of the American Society of Nephrology: JASN, 2020, 31, 2184-2192.	6.1	9
13	An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28Âdays to <â€‰6Âyears with chronic kidney disease receiving dialysis. Pediatric Nephrology, 2019, 34, 145-154.	1.7	16
14	Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. Nephrology Dialysis Transplantation, 2019, 34, 2057-2065.	0.7	73
15	Vitamin D sterols increase FGF23 expression by stimulating osteoblast and osteocyte maturation in CKD bone. Bone, 2019, 127, 626-634.	2.9	21
16	Unraveling the osteocyte in CKD-MBD postâ€“renal transplantation. Kidney International, 2019, 96, 1059-1061.	5.2	5
17	Elevated Fibroblast Growth Factor 23 Levels Are Associated With Greater Diastolic Dysfunction in ESRD. Kidney International Reports, 2019, 4, 1748-1751.	0.8	6
18	Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease Patients. Kidney International Reports, 2019, 4, 1742-1748.	0.8	5

#	Article	IF	Citations
19	Racial differences in bone histomorphometry in children and young adults treated with dialysis. Bone, 2019, 127, 114-119.	2.9	6
20	Mechanism of Action and Clinical Attributes of AuryxiaÂ® (Ferric Citrate). Drugs, 2019, 79, 957-968.	10.9	24
21	Racial-ethnic differences in chronic kidney disease-mineral bone disorder in youth on dialysis. Pediatric Nephrology, 2019, 34, 107-115.	1.7	7
22	Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease. Haematologica, 2018, 103, e141-e142.	3.5	38
23	FGF23 and Left Ventricular Hypertrophy in Children with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 45-52.	4.5	72
24	Non-renal-Related Mechanisms of FGF23 Pathophysiology. Current Osteoporosis Reports, 2018, 16, 724-729.	3.6	23
25	Impaired osteocyte maturation in the pathogenesis of renal osteodystrophy. Kidney International, 2018, 94, 1002-1012.	5.2	26
26	Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients. Pediatric Nephrology, 2018, 33, 2137-2142.	1.7	13
27	Skeletal Consequences of Nephropathic Cystinosis. Journal of Bone and Mineral Research, 2018, 33, 1870-1880.	2.8	20
28	Increased serum hepcidin contributes to the anemia of chronic kidney disease in a murine model. Haematologica, 2017, 102, e85-e88.	3.5	17
29	Fractures and Osteomalacia in a Patient Treated With Frequent Home Hemodialysis. American Journal of Kidney Diseases, 2017, 70, 445-448.	1.9	13
30	Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder. Current Osteoporosis Reports, 2017, 15, 198-206.	3.6	22
31	Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow. Haematologica, 2017, 102, e427-e430.	3.5	93
32	Racialâ€“ethnic disparities in mortality and kidney transplant outcomes among pediatric dialysis patients. Pediatric Nephrology, 2017, 32, 685-695.	1.7	32
33	MRI with ferumoxytol: A single center experience of safety across the age spectrum. Journal of Magnetic Resonance Imaging, 2017, 45, 804-812.	3.4	40
34	Development of a translational research pathway at the David Geffen School of Medicine University of California, Los Angeles. International Journal of Medical Education, 2017, 8, 334-335.	1.2	1
35	Bone Canopies in Pediatric Renal Osteodystrophy. PLoS ONE, 2016, 11, e0152871.	2.5	5
36	Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice. American Journal of Physiology - Renal Physiology, 2016, 311, F1369-F1377.	2.7	54

#	Article	IF	Citations
37	Combining exercise and growth hormone therapy: how can we translate from animal models to chronic kidney disease children?. Nephrology Dialysis Transplantation, 2016, 31, 1191-1194.	0.7	1
38	Fibroblast Growth Factor 23 and Risk of CKD Progression in Children. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1989-1998.	4.5	64
39	Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytol. Pediatric Radiology, 2016, 46, 1332-1340.	2.0	28
40	Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients. Pediatric Nephrology, 2016, 31, 661-669.	1.7	30
41	Fracture Burden and Risk Factors in Childhood CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 543-550.	6.1	107
42	Fourâ€dimensional, multiphase, steadyâ€state imaging with contrast enhancement (MUSIC) in the heart: A feasibility study in children. Magnetic Resonance in Medicine, 2015, 74, 1042-1049.	3.0	49
43	Osteocytic Protein Expression Response to Doxercalciferol Therapy in Pediatric Dialysis Patients. PLoS ONE, 2015, 10, e0120856.	2.5	22
44	Primary osteoblast-like cells from patients with end-stage kidney disease reflect gene expression, proliferation, and mineralization characteristics ex vivo. Kidney International, 2015, 87, 593-601.	5.2	22
45	Altered Osteocyte-Specific Protein Expression in Bone after Childhood Solid Organ Transplantation. PLoS ONE, 2015, 10, e0138156.	2.5	16
46	Disordered FGF23 and Mineral Metabolism in Children with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 344-353.	4.5	128
47	FGF23 protein expression in coronary arteries is associated with impaired kidney function. Nephrology Dialysis Transplantation, 2014, 29, 1525-1532.	0.7	46
48	Antibacterial Responses by Peritoneal Macrophages Are Enhanced Following Vitamin D Supplementation. PLoS ONE, 2014, 9, e116530.	2.5	26
49	Idiopathic juvenile osteoporosis: a cross-sectional single-centre experience with bone histomorphometry and quantitative computed tomography. Pediatric Rheumatology, 2013, 11, 6.	2.1	20
50	Early Skeletal and Biochemical Alterations in Pediatric Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 146-152.	4.5	144
51	Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney International, 2011, 79, 112-119.	5.2	148
52	Value of the New Bone Classification System in Pediatric Renal Osteodystrophy. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1860-1866.	4.5	92
53	Circulating Fibroblast Growth Factor 23 in Patients with End-Stage Renal Disease Treated by Peritoneal Dialysis Is Intact and Biologically Active. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 578-585.	3.6	205
54	Relationship between Plasma Fibroblast Growth Factor-23 Concentration and Bone Mineralization in Children with Renal Failure on Peritoneal Dialysis. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 511-517.	3.6	137

#	Article	IF	Citations
55	Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols. Pediatric Nephrology, 2009, 24, 1355-1361.	1.7	16
56	Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone, 2009, 45, 1161-1168.	2.9	239
57	Hepcidinâ€"A Potential Novel Biomarker for Iron Status in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1051-1056.	4.5	279
58	Technical Approach to Iliac Crest Biopsy. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, S164-S169.	4.5	56
59	Are new vitamin D analogues in renal bone disease superior to calcitriol?. Pediatric Nephrology, 2005, 20, 393-398.	1.7	32
60	Sevelamer Controls Parathyroid Hormoneâ€"Induced Bone Disease as Efficiently as Calcium Carbonate without Increasing Serum Calcium Levels during Therapy with Active Vitamin D Sterols. Journal of the American Society of Nephrology: JASN, 2005, 16, 2501-2508.	6.1	84
61	Reply to the letter from J. I. Minguela and R. Ruiz-de-Gauna. Pediatric Nephrology, 2004, 19, 947.	1.7	0
62	Special aspects of renal osteodystrophy in children. Seminars in Nephrology, 2004, 24, 69-77.	1.6	24
63	Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney International, 2003, 63, 1801-1808.	5.2	119
64	Cardiovascular calcification in endâ€stage renal disease. Nephrology Dialysis Transplantation, 2002, 17, 336-339.	0.7	83
65	Adynamic Renal Osteodystrophy. Journal of the American Society of Nephrology: JASN, 2001, 12, 1978-1985.	6.1	68
66	Growth Retardation in Children with Chronic Renal Failure. Journal of Bone and Mineral Research, 1999, 14, 1680-1690.	2.8	77
67	Bone disease in children and adolescents undergoing successful renal transplantation. Kidney International, 1998, 53, 1358-1364.	5.2	136
68	Aluminium-related Bone Disease in Children with Renal Failure. , 1998, , 109-132.		0
69	Psychological distress and treatment adherence among children on dialysis. Pediatric Nephrology, 1997, 11, 604-606.	1.7	32
70	The management of renal osteodystrophy. Pediatric Nephrology, 1996, 10, 651-653.	1.7	20
71	Parathyroid gland function in secondary hyperparathyroidism. Pediatric Nephrology, 1996, 10, 359-363.	1.7	6
72	Pediatric Renal Osteodystrophy. Seminars in Dialysis, 1996, 9, 347-352.	1.3	1

#	Article	IF	Citations
73	Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney International, 1994, 45, 253-258.	5.2	185
74	Optimal Management of Renal Osteodystrophy in Children Treated with CAPD and CCPD. Seminars in Dialysis, 1994, 7, 435-441.	1.3	3
75	Disodium ethylenediaminetetraacetate: adverse effects in dialyzed children. Pediatric Nephrology, 1993, 7, 182-184.	1.7	6
76	Lipoproteins in Children Treated with Continuous Peritoneal Dialysis. Pediatric Research, 1991, 29, 155-159.	2.3	21
77	Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney International, 1988, 33, 975-982.	5.2	159